Photodynamic therapy

Photodermatology

Volumn , Issue , 2007, Pages 369-388

  Ibbotson, Sally H ^a   Szeimies, Rolf Markus ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873414296     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (125)

1. Szeimies RM, Dräger J, Abels C, et al. History of photodynamic therapy in dermatology. In: Calzavara-Pinton PG, Szeimies RM, Ortel B, eds. Photodynamic Therapy and Fluorescence Diagnosis in Dermatology. Amsterdam: Elsevier, 2001:3-16.
2. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Mol Immunol 2003; 39:1133-1136.
3. Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2004; 30:264-271.
4. Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002; 146:178-188.
5. Karrer S, Abels C, Landthaler M, et al. Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol 2000; 80:26-27.
6. Touma D, Yaar M, Whitehead S, et al. Short incubation S-ALA photodynamic therapy for treatment of actinic keratoses and facial photodamage. Arch Dermatol 2004; 140:33-40.
7. Szeimies RM, Karrer S, Abels C, et al. Photodynamic therapy in dermatology. In: Krutmann J, Honigsmann H, Elmets CA, et al., eds. Dermatological Phototherapy and Photodiagnostic Methods. Berlin: Springer, 2001:209-247.
8. Schweitzer VG. Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients. Laryngoscope 2001; 111:1091-1098.
9. Morton CA, Brown SB, Collins S, et al. Guidelines for topical phototherapy therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146:552-567.
10. Liu Y, Viau G, Bissonnette R. Multiple large-surface photodynamic therapy sessions with topical or systemic aminolevulinic acid and blue light in UV-exposed hairless mice. J Cutan Med Surg 2004; 8:131-139.
11. Stender IM, Bech-Thomsen N, Poulsen T, et al. Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem Photobiol 1997; 66:493-496.
12. Baas P, Saarnak AE, Oppelaar H, et al. Photodynamic therapy with meso-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study. Br J Dermatol 2001; 145:75-78.
13. Lui H, Hobbs L, Tope WD, et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes. Two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 2004; 140:41-46.
14. Brancaleon L, Moseley H. Lasers and non-laser light sources for photodynamic therapy. Lasers Med Sci 2002; 17:173-186.
15. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55:145-157.
16. Ormrod D, Jarvis B. Topical aminolevulinic acid HCl photodynamic therapy. Am J Clin Dermatol 2000; 1:133-139.
17. Clark C, Bryden A, Dawe RS, et al. Topical 5-aminolaevulinc acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed 2003; 19:134-141.
18. Moseley H, Ibbotson S, Woods J, et al. Clinical and research applications of photodynamic therapy in dermatology: Experience of the Scottish PDT Centre. Lasers Surg Med 2006; 38:403-416.
19. Moseley H. Light distribution and calibration of commercial PDT LED arrays. Photochem Photobiol Sci 2005; 4:911-914.
20. Juzeniene A, Juzenas P, Ma LW, et al. Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy. Lasers Med Sci 2004; 19:139-149.
21. Ericson MB, Sandberg C, Stenquist B, et al. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 2004; 151:1204-1212.
22. Moseley H. Total effective fluence: a useful concept in photodynamic therapy. Lasers Med Sci 1996; 11:139-143.
23. Robinson DJ, de Bruijn HS, Star WM, et al. Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol 2003; 77:319-323.
24. Lieb S, Szeimies RM, Lee G. Self-adhesive thin films for topical delivery of 5-aminolevulinic acid. Eur J Pharm Biopharm 2002; 53:99-106.
25. Zelickson B, Counters J, Coles C, et al. Light patch: preliminary report of a novel form of blue light delivery for the treatment of actinic keratosis. Dermatol Surg 2005; 31:375-378.
26. McCarron PA, Donnelly RF, Zawislak A, et al. Evaluation of a water-soluble bioadhesive patch for photodynamic therapy of vulval lesions. Int J Pharm 2005; 293:11-23.
27. Moseley H, Allen JW, Ibbotson S, et al. Ambulatory photodynamic therapy: a new concept in delivering photodynamic therapy. Br J Dermatol 2006; 154:747-750.
28. Ibbotson SH. How to treat a superficial basal cell carcinoma with topical photodynamic therapy in Dundee. Photodiagn Photodyn Ther 2006; 3:128-131.
29. Szeimies RM, Landthaler M, Karrer S. Non-oncologic indications for ALA-PDT. J Derm Treat 2002; 13(suppl 1):S13-S18.
30. Grapengiesser S, Gudmundsson F, Larko O, et al. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27:493-497.
31. Holmes MV, Dawe RS, Ferguson J, et al. A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop®) for pain relief during topical photodynamic therapy. Br J Dermatol 2004; 150:337-340.
32. Langan SM, Collins P. Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutetic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolaevulinic acid-photodynamic therapy for extensive scalp actinic keratoses. Br J Dermatol 2006; 154:146-149.
33. Wiegell SR, Stender I-M, Na R, et al. Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol 2003; 139:1173-1177.
34. Clark C, Dawe RS, Moseley H, et al. The characteristics of erythema induced by topical 5-aminolaevulinic acid photodynamic therapy. Photodermatol Photoimmunol Photomed 2004; 20:105-107.
35. Monfrecola G, Procaccini EM, D'Onofrio D, et al. Hyperpigmentation induced by topical 5-aminolaevulinic acid plus visible light. J Photochem Photobiol B-Biol 2002; 68:147-155.
36. Rhodes LE, Tsoukas MM, Anderson RR, et al. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PplX phototoxicity in human skin. J Invest Dermatol 1997; 108:87-91.
37. Wolf P, Fink-Puches R, Reimann-Weber A, et al. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology 1997; 194:53-54.
38. Varma S, Holt PJA, Anstey AV. Erythroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br J Dermatol 2000; 142:825-826.
39. Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. Br J Dermatol 2000; 143:1270-1274.
40. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47:258-262.
41. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix®) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Derm Treat 2003; 14:99-106.
42. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy (PDT) for non-melanoma skin cancer-an international consensus. J Am Acad Dermatol. In press.
43. Sidoroff A. Actinic keratosis. In: Calzavara-Pinton PG, Szeimies RM, Ortel B, eds. Photodynamic Therapy and Fluorescence Diagnosis in Dermatology. Amsterdam: Elsevier, 2001:199-216.
44. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004; 140:41-46.
45. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48:227-232.
46. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004; 77:115-121.
47. Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003; 148:539-543.
48. Morton CA, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ. Arch Dermatol 2006; 142:729-735.
49. Soler AM, Warloe T, Berner A, et al. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolevulinatebased photodynamic therapy alone and with prior curettage. Br J Dermatol 2001; 145: 467-471.
50. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000; 142:338-339.
51. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 2003; 149:1242-1249.
52. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140:17-23.
53. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144:832-840.
54. Kuijpers DI, Smeets NW, Krekels GA, et al. Photodynamic therapy as adjuvant treatment of extensive basal cell carcinoma treated with Mohs micrographic surgery. Dermatol Surg 2004; 30:794-798.
55. Stender IM, Na R, Fogh H, et al. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 2000; 355:963-966.
56. Stender IM, Wulf CH. Photodynamic therapy of recalcitrant warts with 5-aminolevulinic: a retrospective analysis. Acta Dermato-Venereol 1999; 79:400-401.
57. Stender IM, Lock-Anderson J, Wulf HC. Recalcitrant hand and foot warts successfully treated with photodynamic therapy with topical 5-aminolaevulinic acid: a pilot study. Clin Exp Dermatol 1999; 24:154-159.
58. Schroeter CA, Pleuins J, van Nispentot Pannerden C, et al. Photodynamic therapy: new treatment for therapy-resistant plantar warts. Dermatol Surg 2005; 31:71-75.
59. Mizuki D, Kaneko T, Hanada K. Successful treatment of topical photodynamic therapy using 5-aminolevulinic acid for plane warts. Br J Dermatol 2003; 149:1087-1088.
60. Smucler R, Jatsova E. Comparative study of aminolevulinic acid photodynamic therapy plus pulsed dye laser versus pulsed dye laser alone in treatment of viral warts. Photomed Laser Surg 2005; 23:202-205.
61. Frank RG, Bos JD, Meulen FW, et al. Photodynamic therapy for condylomata acuminata with local application of 5-aminolevulinic acid. Genitourin Med 1996; 72:70-71.
62. Fehr MK, Hornung R, Degen A, et al. Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med 2002; 30:273-279.
63. Wang XL, Wang HW, Wang HS, et al. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. Br J Dermatol 2004; 151:880-885.
64. Karrer S, Szeimies RM, Abels C, et al. Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 1999; 140:935-938.
65. Moiin A. Photodynamic therapy for molluscum contagiosum infection in HIV-coinfected patients: review of 6 patients. J Drugs Dermatol 2003; 2:637-639.
66. Gold MH, Boring MM, Bridges TM, et al. The successful use of ALA-PDT in the treatment of recalcitrant molluscum contagiosum. J Drugs Dermatol 2004; 3:187-190.
67. Cunliffe WJ, Goulden V. Phototherapy and acne vulgaris. Br J Dermatol 2000; 142:855-856.
68. Morton CA, Scholefield RD, Whitehurst C, et al. An open study to determine the efficacy of blue light in the treatment of mild to moderate acne. J Dermatol Treat 2005; 16:219-223.
69. Lee WLS, Shalita AR, Poh-Fitzpatrick MB. Comparative studies of porphyrin production in Propionibacterium acnes and Propionibacterium granulosum. J Bacteriol 1978; 133:811-815.
70. Kjeldstad B, Johnsson A. An action spectrum for blue and near ultraviolet inactivation of Propionibacterium acnes: with emphasis on a possible porphyrin photosensitization. Photochem Photobiol 1986; 43:67-70.
71. Arakane K, Ryu A, Hayashi C, et al. Singlet oxygen (1 delta g) generation from coproporphyrin in Propionibacterium acnes on irradiation. Biochem Biophys Res Commun 1996; 223:578-582.
72. Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. Br J Dermatol 2000; 142:973-978.
73. Hongcharu W, Taylor CR, Chang Y, et al. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000; 115:183-192.
74. Pollock B, Turner D, Stringer MR, et al. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol 2004; 151:616-622.
75. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol 2006; 154:969-976.
76. Hörfelt C, Funk J, Frohm-Nilsson M, et al. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006; 155:608-613.
77. Gold M, Bridges TM, Bradshaw VL, et al. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol 2004; 3(1 suppl):S32-S35.
78. Strauss RM, Pollock B, Stables GI, et al. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol 2005; 152:803-804.
79. Calzavara-Pinton PG, Venturini M, Capezzera R, et al. Photodynamic therapy of interdigital mycoses of the feet with topical application of 5-aminolevulinic acid. Photodermatol Photoimmunol Photomed 2004; 20:144-147.
80. Donnelly RF, McCarron PA, Lightowler JM, et al. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J Controlled Release 2005; 103:381-392.
81. Silver H. Psoriasis vulgaris treated with hematoporphyrin. Arch Dermatol Syphilol 1937; 36:1118-1119.
82. Boehncke WH, König K, Kaufmann R, et al. Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo. Arch Dermatol Res 1994; 286:300-303.
83. Fritsch C, Lehmann P, Stahl W, et al. Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Br J Cancer 1999; 79:1603-1608.
84. Boehncke WH, Sterry W, Kaufmann R. Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet 1994; 343:801.
85. Weinstein GD, McCullough JL, Jeffes EW, et al. Photodynamic therapy (PDT) of psoriasis with topical delta aminolevulinic acid (ALA): a pilot dose-ranging study. Photodermatol Photoimmunol Photomed 1994; 10:92.
86. Collins P, Robinson DJ, Stringer MR, et al. The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 1997; 137:743-749.
87. Robinson DJ, Collins P, Stringer MR, et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol 1999; 79:451-455.
88. Stringer MR, Collins P, Robinson DJ, et al. The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. J Invest Dermatol 1996; 107:76-81.
89. Radakovic-Fijan S, Blecha-Thathammer U, Schleyer V, et al. Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observed-blinded study. Br J Dermatol 2005; 152:279-283.
90. Schleyer V, Radakovic-Fijan S, Karrer S, et al. Disappointing results and low tolerability of photo-dynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study. J Eur Acad Dermatol 2006; 20:823-828.
91. Beattie PE, Dawe RS, Ferguson J, et al. Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy. Clin Exp Dermatol 2004; 29:560-562.
92. Malik Z, Ehrenberg B, Faraggi A. Inactivation of erythrocytic, lymphocytic and myelocytic leukemic cells by photoexcitation of endogenous porphyrins. J Photochem Photobiol B Biol 1989; 4:195-205.
93. Boehncke WH, Konig K, Rück A, et al. In vitro and in vivo effects of photodynamic therapy in cutaneous T-cell lymphoma. Acta Dermato-Venereol 1994; 74:201-205.
94. Rittenhouse-Diakun K, van Leengoed H, Morgan J, et al. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor deltaaminolevulinic acid (ALA). Photochem Photobiol 1995; 61:523-528.
95. Boehncke WH, Rück A, Naumann J, et al. Comparison of sensitivity towards photodynamic therapy of cutaneous resident and infiltrating cell types in vitro. Lasers Surg Med 1996; 19:451-457.
96. Grebenova D, Cajthamlova H, Bartosova J, et al. Selective destruction of leukaemic cells by photo-activation of 5-aminolaevulinic acid-induced protoporphyrin IX. J Photochem Photobiol B Biol 1998; 47:74-81.
97. Wolf P, Fink-Puches R, Cerroni L, et al. Photodynamic therapy for mycosis fungoides after topical photosensitisation with 5-aminolevulinic acid. J Am Acad Dermatol 1994; 31:678-680.
98. Ammann R, Hunziker T. Photodynamic therapy for mycosis fungoides after topical photosensitisation with 5-aminolevulinic acid. J Am Acad Dermatol 1995; 33:541.
99. Orenstein A, Halik J, Tamir J, et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatologic Surg 2000; 26:765-769.
100. Edstrom DW, Porwit A, Ros AM. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Dermato-Venereol 2001; 81:184-188.
101. Markham T, Sheahan K, Collins P. Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol 2001; 144:1262-1263.
102. Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol 2002; 27:516-518.
103. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-aminolevulinic acid sensitisation and laser irradiation. Br J Dermatol 1994; 130:743-751.
104. Coors EA, von den Driesch P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol 2004; 50:363-367.
105. Umegaki N, Moritsugu R, Katoh S, et al. Photodynamic therapy may be useful in debulking cutaneous lymphoma prior to radiotherapy. Clin Exp Dermatol 2004: 29:42-45.
106. Berroeta L, Lewis-Jones MS, Evans AT, et al. Woringer-Kolopp (localised pagetoid reticulosis) treated with topical photodynamic therapy (PDT). Clin Exp Dermatol 2005; 31:1-2.
107. Stender IM, Wulf HC. Photodynamic therapy with 5-aminolaevulinic acid in the treatment of actinic cheilitis. Br J Dermatol 1996; 135:454-456.
108. Hauschild A, Lischner S, Lange-Asschenfeldt B, et al. Treatment of actinic cheilitis using photo-dynamic therapy with methylaminolevulinate: report of three cases. Dermatol Surg 2005; 31:1344-1348.
109. Sieron A, Adamek M, Kawczyk-Krupka A, et al. Photodynamic therapy (PDT) using topically applied delta-aminolevulinic acid (ALA) for the treatment of oral leukoplakia. J Oral Pathol Med 2003; 32:330-336.
110. Chen HM, Chen CT, Yang H, et al. Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Oral Oncol 2004; 40:630-637.
111. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. Photochem Photobiol B Biol 1995; 29:53-57.
112. Stables GI, Stringer MR, Robinson DJ, et al. Erythroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy. Br J Dermatol 1999; 140:514-517.
113. Lee MR, Ryman W. Erythroplasia of Queyrat treated with topical methyl aminolevulinate photodynamic therapy. Australas J Dermatol 2005; 46:196-198.
114. Henta T, Itoh Y, Kobayashi M, et al. Photodynamic therapy for inoperable vulval Paget's disease using delta-aminolaevulinic acid: successful management of a large skin lesion. Br J Dermatol 1999; 141:347-349.
115. Zollo JD, Zeitouni NC. The Roswell Park Cancer Institute experience with extramammary Paget's disease. Br J Dermatol 2000; 142:59-65.
116. Shieh S, Dee AS, Cheney RT, et al. Photodynamic therapy for the treatment of extramammary Paget's disease. Br J Dermatol 2002; 146:1000-1005.
117. Madan V, Loncaster J, Allan D, et al. Extramammary Paget's disease treated with topical and systemic photodynamic therapy. Photodiagn Photodyn Ther 2005; 2:309-311.
118. Martin Hirsch PL, Whitehurst C, Buckley CH, et al. Photodynamic treatment for lower genital tract intraepithelial neoplasia. Lancet 1998; 351:1403.
119. Hillemanns P, Untch M, Dannecker C, et al. Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid. Int J Cancer 2000; 85:649-653.
120. Fehr MK, Hornung R, Schwarz VA, et al. Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevlinic acid. Gynecol Oncol 2001; 80:62-66.
121. Abel-Hady E-S, Martin-Hirsch P, Duggan-Keen M, et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 2001; 61:192-196.
122. Bissonnette R, Shapiro J, Zeng H, et al. Topical photodynamic with 5-aminolaevulinic acid does not induce hair regrowth inpatients with extensive alopecia areata. Br J Dermatol 2000; 143: 1032-1035.
123. Ackermann G, Abels C, Baumker W, et al. Simulations on the selectivity of 5-aminolevulinic acid-induced fluorescence in vivo. J Photochem Photobiol B: Biol 1998; 47:121-128.
124. Ericson MB, Sandberg C, Gudmundson F, et al. Fluorescence contrast and threshold limit: implications for photodynamic diagnosis of basal cell carcinoma. J Photochem Photobiol B: Biol 2003; 69:121-127.
125. Baumker W, Abels C, Szeimies RM. Fluorescence diagnosis and photodynamic therapy in dermatology. Med Laser Appl 2003; 18:47-56.